Natco Pharma gets DCGI nod to sell hepatitis C treatment drug
Drug major Natco PharmaBSE -0.52 % has got approval from the Drugs Controller General of India (DCGI) to sell generic version of Daclatasvir, which is used for treatment of chronic hepatitis C.
In a BSE filing today, Natco Pharma said: “It is the first company in India to get approval for generic Daclatasvir Dihydrochloride (Daclatasvir) tablets, 30 mg & 60 mg, from the Drugs Controller General (India).”
Daclatasvir is the first-in-class NS5A inhibitor used in combination with Sofosbuvir for the treatment of patients with chronic hepatitis C virus (HCV) genotype 3 infection. Read More
Google + 
Facebook
WordPress
You must log in to post a comment.